Analysis of Arg834Gln and Val902Glu type 2A von Willebrand disease mutations. Studies with recombinant von Willebrand factor and correlation with patient characteristics

Talma Englender, Antonella Lattuada, Pier M. Mannucci, J. Evan Sadler, Aida Inbal

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Type 2A yon Willebrand disease (vWD), the most common qualitative form of vWD, is characterized by a relative decrease in circulating intermediate and high molecular weight (HMW) multimers. We studied the biosynthesis of recombinant yon Willebrand factor (vWF) containing each of two type 2A vWD mutations previously reported by us, Arg834Gln and Val902Glu. The structure of recombinant Arg834Gln vWF within transfected COS-7 cells and the secretion of HMW multimers were similar to wild type vWF. The normal transport and secretion of Arg834Gln vWF, categorizes it as a group II type 2A mutation. In contrast, the Val902Glu mutation resulted in intracellular proteolysis of vWF with the generation of a 176-kD fragment and retention of vWF between the endoplasmic reticulum and the Golgi complex. Moreover, the 176-kD fragment was also increased in plasma from patients with the Val902Glu mutation. Significantly impaired secretion and intracellular proteolysis of Val902Glu vWF categorizes a new sub-group of type 2A mutations. The intracellular proteolysis of vWF Val902Glu explains the lack of response to 1-deamino 8-D- arginine vasopressin (DDAVP) in patients who carry the mutation.

Original languageEnglish
Pages (from-to)2788-2794
Number of pages7
JournalBlood
Volume87
Issue number7
Publication statusPublished - Apr 1 1996

Fingerprint

Type 2 von Willebrand Disease
Proteolysis
von Willebrand Factor
Mutation
Molecular weight
Deamino Arginine Vasopressin
Biosynthesis
Molecular Weight
Plasmas
COS Cells
Golgi Apparatus
Endoplasmic Reticulum

ASJC Scopus subject areas

  • Hematology

Cite this

Analysis of Arg834Gln and Val902Glu type 2A von Willebrand disease mutations. Studies with recombinant von Willebrand factor and correlation with patient characteristics. / Englender, Talma; Lattuada, Antonella; Mannucci, Pier M.; Sadler, J. Evan; Inbal, Aida.

In: Blood, Vol. 87, No. 7, 01.04.1996, p. 2788-2794.

Research output: Contribution to journalArticle

@article{f2247c82dd1f4577b975f01ad9c5eab1,
title = "Analysis of Arg834Gln and Val902Glu type 2A von Willebrand disease mutations. Studies with recombinant von Willebrand factor and correlation with patient characteristics",
abstract = "Type 2A yon Willebrand disease (vWD), the most common qualitative form of vWD, is characterized by a relative decrease in circulating intermediate and high molecular weight (HMW) multimers. We studied the biosynthesis of recombinant yon Willebrand factor (vWF) containing each of two type 2A vWD mutations previously reported by us, Arg834Gln and Val902Glu. The structure of recombinant Arg834Gln vWF within transfected COS-7 cells and the secretion of HMW multimers were similar to wild type vWF. The normal transport and secretion of Arg834Gln vWF, categorizes it as a group II type 2A mutation. In contrast, the Val902Glu mutation resulted in intracellular proteolysis of vWF with the generation of a 176-kD fragment and retention of vWF between the endoplasmic reticulum and the Golgi complex. Moreover, the 176-kD fragment was also increased in plasma from patients with the Val902Glu mutation. Significantly impaired secretion and intracellular proteolysis of Val902Glu vWF categorizes a new sub-group of type 2A mutations. The intracellular proteolysis of vWF Val902Glu explains the lack of response to 1-deamino 8-D- arginine vasopressin (DDAVP) in patients who carry the mutation.",
author = "Talma Englender and Antonella Lattuada and Mannucci, {Pier M.} and Sadler, {J. Evan} and Aida Inbal",
year = "1996",
month = "4",
day = "1",
language = "English",
volume = "87",
pages = "2788--2794",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "7",

}

TY - JOUR

T1 - Analysis of Arg834Gln and Val902Glu type 2A von Willebrand disease mutations. Studies with recombinant von Willebrand factor and correlation with patient characteristics

AU - Englender, Talma

AU - Lattuada, Antonella

AU - Mannucci, Pier M.

AU - Sadler, J. Evan

AU - Inbal, Aida

PY - 1996/4/1

Y1 - 1996/4/1

N2 - Type 2A yon Willebrand disease (vWD), the most common qualitative form of vWD, is characterized by a relative decrease in circulating intermediate and high molecular weight (HMW) multimers. We studied the biosynthesis of recombinant yon Willebrand factor (vWF) containing each of two type 2A vWD mutations previously reported by us, Arg834Gln and Val902Glu. The structure of recombinant Arg834Gln vWF within transfected COS-7 cells and the secretion of HMW multimers were similar to wild type vWF. The normal transport and secretion of Arg834Gln vWF, categorizes it as a group II type 2A mutation. In contrast, the Val902Glu mutation resulted in intracellular proteolysis of vWF with the generation of a 176-kD fragment and retention of vWF between the endoplasmic reticulum and the Golgi complex. Moreover, the 176-kD fragment was also increased in plasma from patients with the Val902Glu mutation. Significantly impaired secretion and intracellular proteolysis of Val902Glu vWF categorizes a new sub-group of type 2A mutations. The intracellular proteolysis of vWF Val902Glu explains the lack of response to 1-deamino 8-D- arginine vasopressin (DDAVP) in patients who carry the mutation.

AB - Type 2A yon Willebrand disease (vWD), the most common qualitative form of vWD, is characterized by a relative decrease in circulating intermediate and high molecular weight (HMW) multimers. We studied the biosynthesis of recombinant yon Willebrand factor (vWF) containing each of two type 2A vWD mutations previously reported by us, Arg834Gln and Val902Glu. The structure of recombinant Arg834Gln vWF within transfected COS-7 cells and the secretion of HMW multimers were similar to wild type vWF. The normal transport and secretion of Arg834Gln vWF, categorizes it as a group II type 2A mutation. In contrast, the Val902Glu mutation resulted in intracellular proteolysis of vWF with the generation of a 176-kD fragment and retention of vWF between the endoplasmic reticulum and the Golgi complex. Moreover, the 176-kD fragment was also increased in plasma from patients with the Val902Glu mutation. Significantly impaired secretion and intracellular proteolysis of Val902Glu vWF categorizes a new sub-group of type 2A mutations. The intracellular proteolysis of vWF Val902Glu explains the lack of response to 1-deamino 8-D- arginine vasopressin (DDAVP) in patients who carry the mutation.

UR - http://www.scopus.com/inward/record.url?scp=0029876805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029876805&partnerID=8YFLogxK

M3 - Article

VL - 87

SP - 2788

EP - 2794

JO - Blood

JF - Blood

SN - 0006-4971

IS - 7

ER -